LSTA
LISATA THERAPEUTICS, INC.Company Information
- Company Name
- LISATA THERAPEUTICS, INC.
- CIK
- CIK0000320017
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LSTA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LSTA
SEC filing data through
Insider Sentiment
- Last purchase
- 2021-12-08
- Last sale
- —
- Shares purchased (TTM)
- 33,785
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,030,706
- Shares outstanding
- 9,106,000
- Ownership
- 11.32%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 57.94%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 10 | 13 | 16 | 19 | 17 | 20 | 16 | 20 | 28 | 22 | 23 | 32 | ||||||
| Marketable Securities | - | - | 0 | 0 | 5 | 6 | 15 | 16 | 10 | 22 | 28 | 22 | ||||||
| Accounts Receivable Net | - | - | - | 1 | 1 | 1 | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | 0 | - | - | - | 1 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 3 | 3 | ||||||
| Assets Current | 11 | 14 | 18 | 22 | 25 | 29 | 35 | 38 | 42 | 48 | 54 | 57 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Finite Lived Intangible Assets Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 11 | 14 | 18 | 22 | 25 | 29 | 35 | 38 | 43 | 48 | 55 | 58 | ||||||
Liabilities | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Accrued Liabilities Current | 2 | 3 | 2 | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Current | 3 | 3 | 3 | 5 | 4 | 4 | 6 | 5 | 4 | 5 | 7 | 5 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 3 | 3 | 3 | 5 | 4 | 4 | 6 | 5 | 5 | 5 | 7 | 5 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 581 | 581 | 580 | 580 | 579 | 579 | 578 | 578 | 578 | 577 | 577 | 576 | ||||||
| Treasury Stock Common Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -572 | -569 | -565 | -562 | -557 | -553 | -548 | -543 | -539 | -533 | -528 | -523 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 8 | 11 | 15 | 17 | 21 | 25 | 30 | 34 | 38 | 43 | 48 | 53 | ||||||
| Minority Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
Common Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Liabilities And Stockholders Equity | 11 | 14 | 18 | 22 | 25 | 29 | 35 | 38 | 43 | 48 | 55 | 58 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 33 | ||||||
| Common Stock Shares Issued | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
Treasury Stock Number Of Shares And Restriction Disclosures | ||||||||||||||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLISATA THERAPEUTICS, INC. (LSTA) — SEC Financial Statements & Analysis
LISATA THERAPEUTICS, INC. (LSTA) is a pharmaceutical preparations company, incorporated in DE. LISATA THERAPEUTICS, INC. trades on Nasdaq as: LSTA. LISATA THERAPEUTICS, INC. (LSTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, LISATA THERAPEUTICS, INC. carries a market cap of $30.96M, a P/E ratio of -2.12x, a P/B ratio of 3.76x, a P/S ratio of 309.60x, an enterprise value of $20.52M, and an EV/EBITDA multiple of -1.25x. On profitability, it posts an operating margin of -16428.00%, a net margin of -14621.00%, a Return on Equity (ROE) of -99.89%, a Return on Assets (ROA) of -80.81%, and a Return on Invested Capital (ROIC) of -282.03%. Per share, it reports EPS of $-1.61, diluted EPS of $-1.61, free cash flow per share of $-1.35, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -90.65% year-over-year, net income growth of -22.73% year-over-year, and EPS growth of -26.99% year-over-year. On the balance sheet, it maintains a current ratio of 3.69x, a quick ratio of 3.50x, working capital of $8.03M, a debt-to-equity ratio of 0.37x, a debt ratio of 0.28, free cash flow of $-12.32M (TTM), and net debt of $-10.44M. Figures sourced from SEC EDGAR.
- Market Cap
- $30.96M
- P/E TTM
- -2.12x
- EPS TTM
- $-1.61
- P/B TTM
- 3.76x
- ROE TTM
- -99.89%
- ROA TTM
- -80.81%
- Debt To Equity
- 0.37x
- Free Cash Flow TTM
- $-12.32M
- Net Revenue TTM Growth 1Y
- -90.65%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is LISATA THERAPEUTICS, INC. in?
LISATA THERAPEUTICS, INC. (LSTA) operates in the Pharmaceutical Preparations industry.
What exchange does LSTA trade on?
LISATA THERAPEUTICS, INC. (LSTA) trades on the Nasdaq.
Where is LISATA THERAPEUTICS, INC. incorporated?
LISATA THERAPEUTICS, INC. is incorporated in DE.
When was LISATA THERAPEUTICS, INC. (LSTA)'s most recent SEC filing?
LISATA THERAPEUTICS, INC. (LSTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is LSTA's market cap?
LISATA THERAPEUTICS, INC. (LSTA) has a market capitalization of $30.96M as of 2026-06-30.
What is LSTA's EPS (earnings per share)?
LISATA THERAPEUTICS, INC. (LSTA)'s trailing twelve month EPS is $-1.61 as of 2026-06-30.
What is LSTA's ROE (return on equity)?
LISATA THERAPEUTICS, INC. (LSTA)'s trailing twelve month Return on Equity (ROE) is -99.89% as of 2026-06-30.
What is LSTA's ROA (return on assets)?
LISATA THERAPEUTICS, INC. (LSTA)'s trailing twelve month Return on Assets (ROA) is -80.81% as of 2026-06-30.
What is LSTA's ROIC (return on invested capital)?
LISATA THERAPEUTICS, INC. (LSTA)'s trailing twelve month Return on Invested Capital (ROIC) is -282.03% as of 2025-06-30.
What is LSTA's EV/EBITDA?
LISATA THERAPEUTICS, INC. (LSTA)'s trailing twelve month EV/EBITDA is -1.25x as of 2026-06-30.